APLS - Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

2024-05-13 23:20:00 ET

Summary

• Apellis Pharmaceuticals' stock struggles post-vasculitis scare from Syfovre injections, impacting its initial market penetration.
• Syfovre continues to lead in GA treatment sales, but faces competition and concerns about its long-term efficacy and safety.
• Despite significant Q1 revenues, APLS's financial health is precarious, with a high cash burn and a need for additional capital.
• I recommend holding Apellis stock, considering it for high-risk investment in a diversified portfolio.

Evaluating Risks and Returns in GA Treatment

Apellis Pharmaceuticals' ( APLS ) stock has yet to fully recover after the flagship geographic atrophy [GA] related to age-related macular degeneration [AMD] treatment, Syfovre, was discovered to cause rare events of vasculitis shortly after its February 2023 approval. Since my last update in December and my hold recommendation, citing some uncertainties, APLS is off 32% compared to SP500 returns of 14.9%....

For further details see: